140 related articles for article (PubMed ID: 30624769)
1. Initiation of Pediatric Clinical Trials for Coagulation Factors: Application of Pharmacokinetics and Allometry to First-in-Pediatric Dose Selection.
Mahmood I
J Clin Pharmacol; 2019 Jun; 59(6):829-834. PubMed ID: 30624769
[TBL] [Abstract][Full Text] [Related]
2. Allometric extrapolation of factors VII, VIII and IX clearance in children from adults.
Mahmood I
J Thromb Haemost; 2012 Aug; 10(8):1609-13. PubMed ID: 22612736
[TBL] [Abstract][Full Text] [Related]
3. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.
Edginton AN; Shah B; Sevestre M; Momper JD
Clin Pharmacokinet; 2013 Aug; 52(8):693-703. PubMed ID: 23588537
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
Mansoor N; Ahmad T; Alam Khan R; Sharib SM; Mahmood I
Am J Ther; 2019; 26(1):e32-e37. PubMed ID: 27574923
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods.
Mahmood I; Cheng A; Brauer E; Humeniuk R
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):767-775. PubMed ID: 26547922
[TBL] [Abstract][Full Text] [Related]
6. A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents.
Mahmood I; Tegenge MA
J Clin Pharmacol; 2019 Feb; 59(2):189-197. PubMed ID: 30192373
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Clearance of Monoclonal and Polyclonal Antibodies and Non-Antibody Proteins in Children: Application of Allometric Scaling.
Mahmood I
Antibodies (Basel); 2020 Aug; 9(3):. PubMed ID: 32764408
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
9. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
Xu Y; Langevin BA; Zhou H; Xu Z
J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225
[TBL] [Abstract][Full Text] [Related]
10. Multistep Unified Models Using Prior Knowledge for the Prediction of Drug Clearance in Neonates and Infants.
Tegenge MA; Mahmood I; Jiang Z; Forshee R
J Clin Pharmacol; 2018 Jul; 58(7):877-884. PubMed ID: 29489016
[TBL] [Abstract][Full Text] [Related]
11. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
Shapiro AD; Korth-Bradley J; Poon MC
Haemophilia; 2005 Nov; 11(6):571-82. PubMed ID: 16236106
[TBL] [Abstract][Full Text] [Related]
12. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
[TBL] [Abstract][Full Text] [Related]
13. Application of Allometric Scaling and Salisbury Rule for the Prediction of Antimalarial Drugs for First-in-Pediatric Dose Selection.
Mahmood I
Eur J Drug Metab Pharmacokinet; 2023 Sep; 48(5):587-594. PubMed ID: 37566210
[TBL] [Abstract][Full Text] [Related]
14. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
Collins PW; Fischer K; Morfini M; Blanchette VS; Björkman S;
Haemophilia; 2011 Jan; 17(1):2-10. PubMed ID: 20731726
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
Björkman S
Haemophilia; 2003 May; 9 Suppl 1():101-8; discussion 109-10. PubMed ID: 12709045
[TBL] [Abstract][Full Text] [Related]
16. Treatment on demand--in vivo dose finding studies.
Escobar MA
Haemophilia; 2003 Jul; 9(4):360-7. PubMed ID: 12828669
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
[TBL] [Abstract][Full Text] [Related]
18. Allometry Is a Reasonable Choice in Pediatric Drug Development.
Liu T; Ghafoori P; Gobburu JV
J Clin Pharmacol; 2017 Apr; 57(4):469-475. PubMed ID: 27649629
[TBL] [Abstract][Full Text] [Related]
19. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
20. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
